Phosphodiesterase Type 5 (PDE5) Inhibitors in Erectile Dysfunction: The Proper Drug for the Proper Patient

被引:78
作者
Corona, Giovanni [2 ,4 ]
Mondaini, Nicola [3 ]
Ungar, Andrea [5 ]
Razzoli, Elisa [6 ]
Rossi, Andrea [6 ]
Fusco, Ferdinando [1 ]
机构
[1] Univ Naples Federico II, Urol Clin, I-80132 Naples, Italy
[2] Univ Florence, Dept Clin Physiopathol, Androl & Sexual Med Unit, Florence, Italy
[3] Univ Florence, Santa Maria Annunziata Hosp, Urol Unit, Florence, Italy
[4] Maggiore Bellaria Hosp, Endocrinol Unit, Azienda Usl Bologna, Bologna, Italy
[5] Univ Florence, Dept Crit Care Med & Surg, Unit Geriatr Cardiol & Med, Florence, Italy
[6] Eli Lilly Italy, Dept Med, Sesto Fiorentino, FI, Italy
关键词
Erectile Dysfunction; PDE5; Inhibitors; Tailored Treatment; PLACEBO-CONTROLLED TRIAL; URINARY-TRACT SYMPTOMS; SEXUAL DYSFUNCTION; HYPOGONADAL MEN; SILDENAFIL CITRATE; TESTOSTERONE GEL; TADALAFIL PHARMACOKINETICS; PENILE REHABILITATION; SEMEN CHARACTERISTICS; DEPRESSIVE SYMPTOMS;
D O I
10.1111/j.1743-6109.2011.02473.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
Introduction. Erectile dysfunction (ED) is a very common multidimensional disorder affecting men worldwide. Physical illness, reaction to life stresses, or an unhappy couple relationship influence clinical outcome. Phosphodiesterase type 5 (PDE5) inhibitors are recognized as efficacious and well tolerated, and are the first-line treatment for ED. Sildenafil, tadalafil, and vardenafil are the most widely used and studied PDE5 inhibitors. Data acquired during a routine diagnostic workup for ED should be taken into account when choosing the best PDE5 inhibitor for the individual patient, creating an individualized treatment plan, and going beyond "experience-based" subjective opinion and unfounded ideas and prejudice regarding currently available drugs. Aim. As the process of matching a given patient's profile to any selected PDE5 inhibitor often relies more on physician's personal convictions than on solid evidence, the aim of this review is to identify the main clinical, demographic, and relational factors influencing the choice of the PDE5 inhibitor to be used for the treatment of ED. Methods. A systematic literature search and current treatment guidelines were evaluated in a systematic manner. Main Outcome Measures. The main clinical, cultural, and demographical factors to be considered for the treatment of ED have been identified. Results. Main factors influencing the choice of the treatment for ED have been described. A short list of items that may help in choosing the right PDE5 inhibitor for the treatment of different patients in daily clinical practice has been prepared. Conclusions. The simple algorithms prepared should be a useful tool to be used in daily practice, which may help in choosing the right treatment for each subject affected by ED. Corona G, Mondaini N, Ungar A, Razzoli E, Rossi A, and Fusco F. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: The proper drug for the proper patient. J Sex Med 2011;8:3418-3432.
引用
收藏
页码:3418 / 3432
页数:15
相关论文
共 119 条
[1]
[Anonymous], ORODISPERSIBLE VARDE
[2]
[Anonymous], EFFICACY UDENAFIL RA
[3]
Effects of sildenafil (Viagra™) administration on seminal parameters and post-ejaculatory refractory time in normal males [J].
Aversa, A ;
Mazzilli, F ;
Rossi, T ;
Delfino, M ;
Isidori, AM ;
Fabbri, A .
HUMAN REPRODUCTION, 2000, 15 (01) :131-134
[4]
Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction [J].
Aversa, A ;
Isidori, AM ;
Spera, G ;
Lenzi, A ;
Fabbri, A .
CLINICAL ENDOCRINOLOGY, 2003, 58 (05) :632-638
[5]
Severe Depressive Symptoms and Cardiovascular Risk in Subjects with Erectile Dysfunction [J].
Bandini, Elisa ;
Fisher, Alessandra D. ;
Corona, Giovanni ;
Ricca, Valdo ;
Monami, Matteo ;
Boddi, Valentina ;
Balzi, Daniela ;
Melani, Cecilia ;
Forti, Gianni ;
Mannucci, Edoardo ;
Maggi, Mario .
JOURNAL OF SEXUAL MEDICINE, 2010, 7 (10) :3477-3486
[6]
Bella AJ, 2006, GERIATR AGING S9, V9, P9
[7]
Treatment of erectile dysfunction reduces psychological distress [J].
Bocchio, Massimo ;
Pelliccione, Fiore ;
Mihalca, Radu ;
Ciociola, Francesco ;
Necozione, Stefano ;
Rossi, Alessandro ;
Francavilla, Felice ;
Francavilla, Sandro .
INTERNATIONAL JOURNAL OF ANDROLOGY, 2009, 32 (01) :74-80
[8]
Hypogonadal Men Nonresponders to the PDE5 Inhibitor Tadalafil Benefit from Normalization of Testosterone Levels with a 1% Hydroalcoholic Testosterone Gel in the Treatment of Erectile Dysfunction (TADTEST Study) [J].
Buvat, Jacques ;
Montorsi, Francesco ;
Maggi, Mario ;
Porst, Hartmut ;
Kaipia, Antti ;
Colson, Marie Helene ;
Cuzin, Beatrice ;
Moncada, Ignacio ;
Martin-Morales, Antonio ;
Yassin, Aksam ;
Meuleman, Eric ;
Eardley, Ian ;
Dean, John Daniel ;
Shabsigh, Ridwan .
JOURNAL OF SEXUAL MEDICINE, 2011, 8 (01) :284-293
[9]
The efficacy and safety of tadalafil: an update [J].
Carson, CC ;
Rajfer, J ;
Eardley, I ;
Carrier, S ;
Denne, JS ;
Walker, DJ ;
Shen, W ;
Cordell, WH .
BJU INTERNATIONAL, 2004, 93 (09) :1276-1281
[10]
The efficacy of sildenafil citrate (Viagra®) in clinical populations:: An update [J].
Carson, CC ;
Burnett, AL ;
Levine, LA ;
Nehra, A .
UROLOGY, 2002, 60 (2B) :12-27